VIVES Partners

VIVES Partners

Venture Capital and Private Equity Principals

Wavre, Walloon Region 1,011 followers

Making science investable

About us

🌱 Empowering Innovation and Driving Growth Across Europe 🌱 At VIVES Partners, we are dedicated to fostering innovation by investing in local, regional, and European start-ups with a strong academic foundation. As managers of the VIVES Funds, our mission is to support groundbreaking ideas at their earliest stages, focusing on seed and early-stage technologies in life sciences, agritech, and engineering. We aim to build world-class technology companies that not only push the boundaries of science and engineering but also drive sustainable growth and make a global impact. 🌍🚀 If you are working on cutting-edge research or pioneering technology, we'd love to connect and explore how we can help turn your vision into reality. #Innovation #Technology #Startups #LifeSciences #Agritech #Engineering #Investment #VIVESPartners

Industry
Venture Capital and Private Equity Principals
Company size
2-10 employees
Headquarters
Wavre, Walloon Region
Type
Privately Held
Founded
2004
Specialties
Cleantech, Biotech, ICT, Technology, startups, pre-seed investment, Funding, Spin-Off, Engineering, and Life Sciences

Locations

  • Primary

    Chemin du Stocquoy

    Wavre, Walloon Region 1300, BE

    Get directions
  • Place de l'université 16

    Bte 27

    Louvain-la-Neuve, Région wallonne 1348, BE

    Get directions

Employees at VIVES Partners

Updates

  • VIVES Partners reposted this

    🌱 Innovating sustainable agriculture: BiocSol, a UCLouvain spinoff! BioCsol, a spin-off from UCLouvain - Université catholique de Louvain, has successfully raised €5,2 million to develop next-generation biopesticides. The groundbreaking solution aims to protect crops while safeguarding the environment—a critical challenge for the agriculture of tomorrow. 🌍 Born in 2023 from Simon Caulier's research at UCLouvain, BioCsol harnesses the power of microorganisms to offer natural, eco-friendly alternatives to traditional chemical pesticides. This approach not only promotes biodiversity but also addresses the urgent need for sustainable agricultural practices. This funding round highlights the potential of university-driven innovation to tackle global challenges 💪 🚀 Congratulations to the BioCsol team for fostering innovation that paves the way for a greener, more sustainable future! #SustainableAgriculture #Biotech #Innovation #Biopesticides | Agri Investment Fund | Boerenbond  | VIVES Partners  | invest.bw  | IMBC SPINNOVA

    • No alternative text description for this image
  • VIVES Partners reposted this

    View profile for Anna Krzyzanowska, graphic

    Adviser at European Commission, DG RTD

    Let’s use the feedback from startups and scaleups. And to ideas from Draghi, Letta and Heitir reports - entrepreneurs need measures which are simple, easy to use and immediately relevant.

    View profile for András G. Inotai, graphic

    Head of Unit, Innovation Policy and Access to Finance, DG Research & Innovation, European Commission; Former Senior Ocean Advisor to European Commissioners; Author of Children's Book "Ping Pong Pants"

    "The first pillar is closing the #innovation gap. Let me start with the good news. Europe's global share of patent applications is on par with the US and China. But only one-third of these are commercially exploited. We are roughly as good as the US at creating start-ups. But when it comes to scale-ups, we are doing much worse than our competitors. We have to close that gap. So we will put research and innovation, science and technology at the heart of our economy. We will invest more and focus better. And we will ensure that our small companies, our start-ups and scale-ups, can thrive here in Europe. We know what needs to be done. A start-up from California can expand and raise money all across the United States. But a start-up in Europe has to deal with 27 different national barriers. We need to make it easier to grow in Europe. For this and many more reasons the first-ever Commissioner for Start-Ups, Research and Innovation will be Ekaterina Zaharieva. Her leadership and experience will be invaluable to get more breakthrough tech from the lab to the market." Read the full speech of European Commission President von der Leyen at the European Parliament Plenary on the new College of Commissioners and its programme: https://lnkd.in/eGR3qvr7 Christoph Kuhn Alessandro Izzo Michiel Scheffer Dan Dionisie Amaryllis Verhoeven Jan Ceyssens Paweł Świeboda Astrid Bartels Serena Borbotti-Frison Lars Frølund Keith Sequeira Jekaterina Novikova Branislav Turcina Massimo Gaudina

    Speech by President von der Leyen at the European Parliament Plenary on the new College of Commissioners and its programme

    Speech by President von der Leyen at the European Parliament Plenary on the new College of Commissioners and its programme

    ec.europa.eu

  • VIVES Partners reposted this

    View organization page for Sunrise, graphic

    8,250 followers

    [New research] Highlights from Dr Martinot Jean-Benoît's presentation at the Congrès du Sommeil in Lille 🇫🇷 Oral appliances that move the jaw forward are proven to improve airway patency (keeping the airway open during sleep), resulting in better breathing and sleep quality for people with obstructive sleep apnea (OSA). Dr Martinot Jean-Benoît's latest research investigated the dose-response relationship between the degree of mandibular protrusion (how far the jaw is advanced) and the reduction of respiratory effort — the extra work required to breathe during sleep, especially during obstructive events. Using at-home mandibular jaw movement analysis, the study involving 93 patients highlighted the added value of monitoring the REMOV metric (a measure of respiratory effort), alongside the traditional apnea-hypopnea index (AHI). Together, these two metrics empower clinicians with a more complete picture of treatment effectiveness, allowing precise adjustments to oral appliances for more personalized and effective care—ultimately improving patient outcomes. A remarkable step forward in sleep medicine—congratulations, Dr Martinot Jean-Benoît 🔭💤

    • No alternative text description for this image
  • VIVES Partners reposted this

    View profile for Sylvie Creteur, graphic

    CEO de IMBC

    Et si vous appreniez que vous risquez de perdre jusqu’à 40 % de votre production ? 🤔 😨 La nouvelle ne serait franchement pas bonne… C’est pourtant une réalité pour nos agriculteurs : chaque année, entre 20 et 40 % des récoltes mondiales sont détruites par des champignons parasites.   La spin-off BiocSol a décidé de s’attaquer de front à cette problématique en créant des solutions innovantes et durables pour protéger les cultures tout en préservant l’environnement et la biodiversité.   Après dix ans de recherche à l’UCLouvain - Université catholique de Louvain et de premiers essais terrain concluants, l’entreprise se lance sur le marché des produits phytosanitaires avec un biopesticide de nouvelle génération. En exploitant des substances spécifiques d’origine microbienne, les biosolutions créées par BiocSol présentent des performances renforcées en termes d’efficacité et de stabilité notamment contre le mildiou des pommes de terre et des raisins.   Moins d’un an après sa création, BiocSol lève 5,2 millions d’euros lors de son premier tour de financement. Cette levée de fonds, soutenue par Agri Investment Fund et VIVES Partners, confirme le fort potentiel du produit sur le marché.   IMBC Spinnova, aux côtés d’invest.bw, participe à hauteur de 500.000 € chacun pour soutenir cette initiative prometteuse.   Nous sommes fiers de soutenir ce projet stratégique pour l’agriculture de demain. 🌱 ♻️ ️ Bravo à Simon Caulier pour le chemin parcouru !   #Environnement #developpementdurable #Biopesticides #AgricultureDeDemain #InnovationAgricole

    • No alternative text description for this image
  • VIVES Partners reposted this

    View organization page for VIVES Partners, graphic

    1,011 followers

    We are pleased to support Generare in its seed funding round! 👏   🦠 Generare is taking bacteria found in soil and breaking down their genetic code to uncover untapped bioactive molecules, called Natural Products (NPs), at unprecedented speed.   🌱 NPs were once the gold-standard for drug-discovery; penicillin being a prime example. They have led to 500+ anticancer, antibiotics and immunosuppressive drugs, yet their discovery in recent years has plateaued even though molecules from microbes are 100x more likely to gain approval than those from plants or chemistry.   🔓 Generare is reopening this critical avenue of discovery and doing so at scale. Using its patent-pending techniques it has already identified 100+ previously unknown molecules.   🚀 We are proud to support such an innovative company utilizing natural products, which we truly believe is the future of the agricultural, biotech and pharma sectors.   👏 Congratulations to Guillaume Vandenesch, Dr Vincent Libis and the Generare team, we can’t wait to see what you do next! Teampact.ventures Galion.exe SynBioVen Saras Capital Better Angle   #seedfunding #biotech #agritech #naturalproducts #funding #syntheticbio #innovation

    • No alternative text description for this image
  • VIVES Partners reposted this

    View organization page for VIVES Partners, graphic

    1,011 followers

    📢 We are delighted to announce our VIVES portfolio company BiocSol has secured €5.2M in seed funding!   📚 Built on a decade of research at Université catholique de Louvain, BiocSol is redefining sustainable agriculture with its next-generation microbial-based solutions. By using secondary metabolites, these eco-friendly innovations deliver enhanced stability and effectiveness, ensuring reliable protection for key crops like potatoes, grapes, and vegetables—paving the way for a more sustainable future in farming.🌱   VIVES co-led the round with Agri Investment Fund bringing in new investors, invest.bw and IMBC SPINNOVA SA onboard 💪   Warm congrats to Denis Payen and Simon Caulier for this incredible milestone   Read the full press release 👇 https://lnkd.in/dvHqmKMU   #agtech #midldew #lateblight #biofungicide #cropcare #sustainability #innovation #agriculture #farming #impact #resilience #UCLouvain

    • No alternative text description for this image
  • VIVES Partners reposted this

    View organization page for VIVES Partners, graphic

    1,011 followers

    💥 Congratulations to NOVADIP Biosciences S.A., a VIVES portfolio company, on receiving FDA IND approval to advance to a Phase 2b/3 clinical trial of NVDX3 for cervical spine fusion!   💪 This milestone represents a pivotal moment for the orthopedic sector and a major step forward for patients suffering from fracture nonunions, which account for 5–10% of all bone traumas—or approximately 2 million impaired fractures annually. The global economic impact of fracture nonunion is staggering, with costs estimated at $20–30 billion per year, driven by medical expenses, prolonged treatments, and productivity losses.   🔬 Backed by robust preclinical and clinical data, NVDX3 has the potential to replace current graft products, offering enhanced safety and superior bone fusion for patients with complex comorbidities, ultimately improving recovery outcomes and surgical success.   As investors in Novadip, we are proud to support this transformative journey, delivering safe and easy-to-use solutions to the patients who need them most.   ✨ This is the perfect timing for Novadip, as the company prepares for its $50M fundraising round!🚀 #funding #nonunion #SpineSurgery #FDAApproval #NVDX3 #HealthTech #ClinicalTrials

    View organization page for NOVADIP Biosciences S.A., graphic

    6,348 followers

    News release // New milestone for Novadip Biosciences We are thrilled to announce that Novadip’s NVDX3 has reached key milestones leading to IND approval from FDA to start phase 2b/3 study in cervical spine fusion 📅Key trial details: • Phase 2b/3 study expected to begin enrollment in H2 2025 across 10 sites in the US. • The FDA-approved IND study will assess the efficacy of NVDX3 compared to standard-of-care treatments in level two cervical spine fusion 📣 Denis Dufrane, MD, PhD, CEO of Novadip, explains: “The trial will accelerate our capability to bring NVDX3 to patients with complex needs, providing them with a better chance of healing compared to standard-of-care treatments. These strategic steps enable us to take NVDX3 to the next level.” Built upon robust preclinical and clinical data, NVDX3 is poised to disrupt current treatment options by offering a single treatment solution for patients at high risk of nonunion due to complex comorbidities such as aging, diabetes, obesity, and smoking. 👉 Stay tuned for more clinical updates #RegenerativeMedicine #SpinalFusion #BoneHealing #ClinicalTrials #CervicalSpineFusion

  • View organization page for VIVES Partners, graphic

    1,011 followers

    💥 Congratulations to NOVADIP Biosciences S.A., a VIVES portfolio company, on receiving FDA IND approval to advance to a Phase 2b/3 clinical trial of NVDX3 for cervical spine fusion!   💪 This milestone represents a pivotal moment for the orthopedic sector and a major step forward for patients suffering from fracture nonunions, which account for 5–10% of all bone traumas—or approximately 2 million impaired fractures annually. The global economic impact of fracture nonunion is staggering, with costs estimated at $20–30 billion per year, driven by medical expenses, prolonged treatments, and productivity losses.   🔬 Backed by robust preclinical and clinical data, NVDX3 has the potential to replace current graft products, offering enhanced safety and superior bone fusion for patients with complex comorbidities, ultimately improving recovery outcomes and surgical success.   As investors in Novadip, we are proud to support this transformative journey, delivering safe and easy-to-use solutions to the patients who need them most.   ✨ This is the perfect timing for Novadip, as the company prepares for its $50M fundraising round!🚀 #funding #nonunion #SpineSurgery #FDAApproval #NVDX3 #HealthTech #ClinicalTrials

    View organization page for NOVADIP Biosciences S.A., graphic

    6,348 followers

    News release // New milestone for Novadip Biosciences We are thrilled to announce that Novadip’s NVDX3 has reached key milestones leading to IND approval from FDA to start phase 2b/3 study in cervical spine fusion 📅Key trial details: • Phase 2b/3 study expected to begin enrollment in H2 2025 across 10 sites in the US. • The FDA-approved IND study will assess the efficacy of NVDX3 compared to standard-of-care treatments in level two cervical spine fusion 📣 Denis Dufrane, MD, PhD, CEO of Novadip, explains: “The trial will accelerate our capability to bring NVDX3 to patients with complex needs, providing them with a better chance of healing compared to standard-of-care treatments. These strategic steps enable us to take NVDX3 to the next level.” Built upon robust preclinical and clinical data, NVDX3 is poised to disrupt current treatment options by offering a single treatment solution for patients at high risk of nonunion due to complex comorbidities such as aging, diabetes, obesity, and smoking. 👉 Stay tuned for more clinical updates #RegenerativeMedicine #SpinalFusion #BoneHealing #ClinicalTrials #CervicalSpineFusion

  • View organization page for VIVES Partners, graphic

    1,011 followers

    📢 We are delighted to announce our VIVES portfolio company BiocSol has secured €5.2M in seed funding!   📚 Built on a decade of research at Université catholique de Louvain, BiocSol is redefining sustainable agriculture with its next-generation microbial-based solutions. By using secondary metabolites, these eco-friendly innovations deliver enhanced stability and effectiveness, ensuring reliable protection for key crops like potatoes, grapes, and vegetables—paving the way for a more sustainable future in farming.🌱   VIVES co-led the round with Agri Investment Fund bringing in new investors, invest.bw and IMBC SPINNOVA SA onboard 💪   Warm congrats to Denis Payen and Simon Caulier for this incredible milestone   Read the full press release 👇 https://lnkd.in/dvHqmKMU   #agtech #midldew #lateblight #biofungicide #cropcare #sustainability #innovation #agriculture #farming #impact #resilience #UCLouvain

    • No alternative text description for this image
  • VIVES Partners reposted this

    View organization page for LMO, graphic

    4,530 followers

    🚀 Exciting progress in European collaboration for Space Situational Awareness (#SSA)! 🌍 The SPRING project, supported by the #EU #EDF programme, has brought together #SMEs across Europe, fostering collaboration to develop cutting-edge Protect & Defend capabilities for both Ground and Space-Based SSA. By leveraging the diverse expertise of small and medium-sized enterprises, the project has accelerated innovation and created novel solutions to ensure the security and sustainability of our space environment. From early-stage threat detection to real-time space object tracking, the SPRING project is empowering SMEs to play a pivotal role in strengthening Europe’s space capabilities. Together, we’re building a safer, more resilient space ecosystem for the future! ✨ #Space #SpaceSecurity #SSP #Innovation #EuropeanCollaboration #SMEs #SpaceSituationalAwareness #SpaceDefense #ProtectAndDefend Aldoria Nurjana Technologies Sybilla Technologies AIKO - Infinite ways to autonomy

Similar pages